Plain-English translation of NCT06102395 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing , an immunotherapy medication, combined with standard chemotherapy as a pre-surgery treatment for advanced head and neck cancer. Half of participants will receive plus chemotherapy, while the other half will receive chemotherapy alone. Both groups receive 2 cycles of treatment before imaging tests determine what happens next—either surgery, radiation, or additional treatment.
Researchers believe that adding this medication to chemotherapy might work better, cause fewer side effects, and be easier to use than chemotherapy alone for patients with locally advanced head and neck cancer. There is currently limited research on this specific combination in Chinese patients with operable head and neck cancer.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the medication combined with chemotherapy or chemotherapy alone, given intravenously over 2 cycles (about 6 weeks). After treatment, imaging scans will determine your next steps—which may include surgery, radiation therapy, or additional treatment. You will have follow-up visits every 3 months for the first year, then every 6 months for the next 3 years, with blood tests and imaging to monitor your response and watch for any side effects.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China